688029 南微医学
已收盘 08-27 15:00:00
资讯
新帖
简况
南微医学：8月23日召开业绩说明会，包括知名机构易鑫安资管的多家机构参与
证券之星 · 08-27 16:42
南微医学：8月23日召开业绩说明会，包括知名机构易鑫安资管的多家机构参与
南微医学(688029)：政策扰动下国内持续稳定 国际化开拓加速布局
中泰证券股份有... · 08-27 11:55
南微医学(688029)：政策扰动下国内持续稳定 国际化开拓加速布局
南微医学大幅上涨 获4家券商增持建议
智选洞察 · 08-26 09:40
南微医学大幅上涨 获4家券商增持建议
东吴证券：给予南微医学买入评级
证券之星 · 08-26 08:25
东吴证券：给予南微医学买入评级
【浙商医药||孙建】南微医学24H1：海外收入亮眼，全年有望延续
杏林建研 · 08-25 20:26
【浙商医药||孙建】南微医学24H1：海外收入亮眼，全年有望延续
南微医学获国联证券买入评级，海外业务高速增长
金融界 · 08-24
南微医学获国联证券买入评级，海外业务高速增长
南微医学(688029)：国内阶段性承压 出海前景广阔
国泰君安证券股... · 08-24
南微医学(688029)：国内阶段性承压 出海前景广阔
国金证券：给予南微医学买入评级
证券之星 · 08-23
国金证券：给予南微医学买入评级
南微医学(688029)：公司24年中期业绩符合预期 海外建设/降本增效两手抓
广发证券股份有... · 08-23
南微医学(688029)：公司24年中期业绩符合预期 海外建设/降本增效两手抓
南微医学(688029)：国际市场销售快速增长 业务毛利率显著提升
国金证券股份有... · 08-23
南微医学(688029)：国际市场销售快速增长 业务毛利率显著提升
南微医学(688029.SH)发布半年度业绩，净利润3.1亿元，同比增长17.47%
智通财经 · 08-22
南微医学(688029.SH)发布半年度业绩，净利润3.1亿元，同比增长17.47%
南微医学：2024年半年度净利润约3.1亿元，同比增加17.47%
每日经济新闻 · 08-22
南微医学：2024年半年度净利润约3.1亿元，同比增加17.47%
南微医学最新公告：上半年净利润3.1亿元 同比增长17.47%
证券之星 · 08-22
南微医学最新公告：上半年净利润3.1亿元 同比增长17.47%
南微医学08月22日主力资金流入47万元 连续3日加仓
市场透视 · 08-22
南微医学08月22日主力资金流入47万元 连续3日加仓
南微医学大跌5.04% 3家券商给予增持建议
智选洞察 · 08-20
南微医学大跌5.04% 3家券商给予增持建议
南微医学(688029.SH)股东Huakang减持期满 合计减持371.51万股
智通财经 · 08-12
南微医学(688029.SH)股东Huakang减持期满 合计减持371.51万股
南微医学获得发明专利授权：“一种三臂夹”
证券之星 · 08-10
南微医学获得发明专利授权：“一种三臂夹”
A股成价值洼地，科创利好催化不断
鹏华基金 · 08-08
A股成价值洼地，科创利好催化不断
【9家上市公司股票获重要股东增持，广安爱众增持金额最高】金十数据8月7日讯，数据显示，按变动截止日期为基准，8月6日，3家上市公司股票遭重要股东减持，南微医学遭重要股东减持73.
美港电讯 · 08-07
【9家上市公司股票获重要股东增持，广安爱众增持金额最高】金十数据8月7日讯，数据显示，按变动截止日期为基准，8月6日，3家上市公司股票遭重要股东减持，南微医学遭重要股东减持73.
8月6日南微医学发布公告，其股东减持73.85万股
证券之星 · 08-06
8月6日南微医学发布公告，其股东减持73.85万股
暂无数据
公司概况
公司名称：
南微医学科技股份有限公司
所属行业：
专用设备制造业
上市日期：
2019-07-22
主营业务：
南微医学科技股份有限公司的主营业务为微创医疗器械的研发、制造和销售。公司主要产品包括内镜诊疗器械、微波消融设备及耗材、一次性内镜。公司内镜诊疗器械主要包括活检类、止血和闭合类、EMR/ESD 类、扩张类、ERCP 类、EUS/EBUS类等六大类60多种上百个规格系列产品，微波消融主要包括微波消融仪和微波消融针系列产品。公司是我国内镜诊疗器械的主要制造商之一，是国内内镜诊疗器械、耗材细分领域中起步较早、创新能力强、产品线丰富、规模优势明显、迈向国际化的行业龙头企业。
发行价格：
52.45
{"stockData":{"symbol":"688029","market":"SH","secType":"STK","nameCN":"南微医学","latestPrice":59.95,"timestamp":1724742000000,"preClose":59.11,"halted":0,"volume":1526171,"delay":0,"floatShares":188000000,"shares":188000000,"eps":2.8326,"marketStatus":"已收盘","marketStatusCode":5,"change":0.84,"latestTime":"08-27 15:00:00","open":59.07,"high":60.76,"low":58.62,"amount":91543900,"amplitude":0.0362,"askPrice":59.95,"askSize":1,"bidPrice":59.94,"bidSize":4,"shortable":0,"etf":0,"ttmEps":2.8326,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1724808600000},"adr":0,"adjPreClose":59.11,"symbolType":"stock_kcb","openAndCloseTimeList":[[1724722200000,1724729400000],[1724734800000,1724742000000]],"highLimit":65.02,"lowLimit":53.2,"ibTradeSell":false,"ibTradeBuySell":true,"totalEquity":187847422,"pbRate":3.05,"roa":"--","roe":"8.37%","epsLYR":2.59,"committee":0.219512,"marketValue":11261000000,"floatMarketCap":11261000000,"peRate":21.1643,"changeRate":0.0142,"turnoverRate":0.0081,"status":0,"afterMarket":{"amount":0,"volume":0,"close":59.95,"buyVolume":0,"sellVolume":0,"time":1724744037153,"indexStatus":"已收盘 08-27 15:30:00","preClose":59.11}},"requestUrl":"/m/hq/s/688029/tweets","defaultTab":"tweets","newsList":[{"id":"2462637158","title":"南微医学：8月23日召开业绩说明会，包括知名机构易鑫安资管的多家机构参与","url":"https://stock-news.laohu8.com/highlight/detail?id=2462637158","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2462637158?lang=zh_cn&edition=full","pubTime":"2024-08-27 16:42","pubTimestamp":1724748130,"startTime":"0","endTime":"0","summary":"eyeMax凭借优质性能获得终端好评，目前市场推广顺利，已在美国多家医院开展试用评估，销售状况良好。尽管国内市场受到价格影响，但其边际利润贡献率仍处于领先地位。答：本次集采是河北牵头多个省份进行，河北省已于 5 月份开始落地执行，其他省份会逐步跟进。公司将积极关注河北以外其他省份的集采政策动态。南微医学主营业务：微创医疗器械的研发、制造和销售。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024082700027111.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688029","BK0251"],"gpt_icon":0},{"id":"2462447188","title":"南微医学(688029)：政策扰动下国内持续稳定 国际化开拓加速布局","url":"https://stock-news.laohu8.com/highlight/detail?id=2462447188","media":"中泰证券股份有...","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2462447188?lang=zh_cn&edition=full","pubTime":"2024-08-27 11:55","pubTimestamp":1724730942,"startTime":"0","endTime":"0","summary":"事件：公司发布2024 半年报。公司单季度收入延续良好增势，主要得益于国内内镜耗材业务的稳定贡献以及海外市场的加速开拓，单季度利润增速有所波动，主要因当期汇兑损益变动较大。公司当前股价对应2024-2026 年18、14、12 倍PE，考虑到公司所处微创诊疗器械行业国产化率低，一次性胆道镜等新产品上市有望推动业绩加速，维持“买入”评级。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024082711555395c7c3fe&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024082711555395c7c3fe&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK0251","688029"],"gpt_icon":0},{"id":"2462984263","title":"南微医学大幅上涨 获4家券商增持建议","url":"https://stock-news.laohu8.com/highlight/detail?id=2462984263","media":"智选洞察","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2462984263?lang=zh_cn&edition=full","pubTime":"2024-08-26 09:40","pubTimestamp":1724636421,"startTime":"0","endTime":"0","summary":"08月26日，南微医学股价大幅上涨，截至09点40分，南微医学上涨5.02%，报59.44元/股，成交3345万元，换手率0.31%。资金动向截止发稿，南微医学获得主力净流出33万元，其中超大单流出146万元，大单流入114万元。主营业务及业绩南微医学公司主营业务为微创医疗器械研发、制造和销售。最新财报显示，今年中报，南微医学实现营业收入13.34亿元，同比增长16.28%，净利润为3.10亿元，同比增长17.47%，基本每股收益为1.66元。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240826095202a1d63c71&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240826095202a1d63c71&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["688029","BK0251"],"gpt_icon":0},{"id":"2462856859","title":"东吴证券：给予南微医学买入评级","url":"https://stock-news.laohu8.com/highlight/detail?id=2462856859","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2462856859?lang=zh_cn&edition=full","pubTime":"2024-08-26 08:25","pubTimestamp":1724631916,"startTime":"0","endTime":"0","summary":"东吴证券股份有限公司朱国广近期对南微医学进行研究并发布了研究报告《2024年H1业绩点评：出海加速，毛利率净利率稳步提升》，本报告对南微医学给出买入评级，当前股价为56.6元。考虑到公司海外市场推广顺利，维持“买入”评级。最新盈利预测明细如下：该股最近90天内共有5家机构给出评级，买入评级4家，增持评级1家；过去90天内机构目标均价为74.9。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024082600001641.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["601555","688029"],"gpt_icon":0},{"id":"2462897620","title":"【浙商医药||孙建】南微医学24H1：海外收入亮眼，全年有望延续","url":"https://stock-news.laohu8.com/highlight/detail?id=2462897620","media":"杏林建研","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2462897620?lang=zh_cn&edition=full","pubTime":"2024-08-25 20:26","pubTimestamp":1724588801,"startTime":"0","endTime":"0","summary":"从2023年到2024H1以来，公司利润端增速持续快于收入端来看，公司战略规划成果显著，展望2024年，公司利润端有望得到持续改善。风险提示市场竞争加剧导致毛利率下降风险、新产品销售不及预期风险、政策性事件等财务摘要表附录：三大报表预测值注意事项往期报告回顾南微医学23A：国内稳步增长，海外高增持续南微医学23Q3：盈利能力恢复，海外市场加速南微医学2023中报点评：疫后复苏持续，可视化出海可期团队成员","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202408252034209f534c63&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202408252034209f534c63&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["159938","688029","BK0251"],"gpt_icon":0},{"id":"2461635171","title":"南微医学获国联证券买入评级，海外业务高速增长","url":"https://stock-news.laohu8.com/highlight/detail?id=2461635171","media":"金融界","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2461635171?lang=zh_cn&edition=full","pubTime":"2024-08-24 18:44","pubTimestamp":1724496256,"startTime":"0","endTime":"0","summary":"8月24日，南微医学获国联证券买入评级，近一个月南微医学获得2份研报关注。研报预计公司2024-2026年营业收入分别为29.13/35.12/42.32亿元，同比分别20.80%/20.57%/20.49%；归母净利润分别为 ...","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://stock.10jqka.com.cn/hks/20240824/c661105977.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tonghuashun","symbols":["601456","688029"],"gpt_icon":0},{"id":"2461503080","title":"南微医学(688029)：国内阶段性承压 出海前景广阔","url":"https://stock-news.laohu8.com/highlight/detail?id=2461503080","media":"国泰君安证券股...","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2461503080?lang=zh_cn&edition=full","pubTime":"2024-08-24 11:19","pubTimestamp":1724469592,"startTime":"0","endTime":"0","summary":"2024H1 汇兑收益减少6210 万元，剔除后归母净利润增速+41%。国内阶段性放缓，海外发展态势迅猛。毛利率稳步提升，控成本效果突出。2024H1 公司毛利率67.94%，其中境内毛利率68.6%，境外毛利率67.5%，均有明显增长，控成本效果有望延续。为抵御贸易摩擦风险，公司的泰国生产基地计划2026 年投产，出海前景广阔。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202408241119579f4e78bd&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202408241119579f4e78bd&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["688029","BK0251"],"gpt_icon":0},{"id":"2461511725","title":"国金证券：给予南微医学买入评级","url":"https://stock-news.laohu8.com/highlight/detail?id=2461511725","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2461511725?lang=zh_cn&edition=full","pubTime":"2024-08-23 16:32","pubTimestamp":1724401956,"startTime":"0","endTime":"0","summary":"国金证券股份有限公司袁维,何冠洲近期对南微医学进行研究并发布了研究报告《国际市场销售快速增长，业务毛利率显著提升》，本报告对南微医学给出买入评级，当前股价为56.6元。最新盈利预测明细如下：该股最近90天内共有5家机构给出评级，买入评级4家，增持评级1家；过去90天内机构目标均价为74.9。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024082300028395.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688029"],"gpt_icon":0},{"id":"2461305915","title":"南微医学(688029)：公司24年中期业绩符合预期 海外建设/降本增效两手抓","url":"https://stock-news.laohu8.com/highlight/detail?id=2461305915","media":"广发证券股份有...","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2461305915?lang=zh_cn&edition=full","pubTime":"2024-08-23 15:11","pubTimestamp":1724397112,"startTime":"0","endTime":"0","summary":"公司业绩符合预期，国内外市场齐发力。公司发布24 年半年报，24 年上半年公司实现营收13.34 亿元，主要系海外市场产品销售数量增加。根据wind，公司24年2 季度实现营收7.14 亿元；归母净利润1.67 亿元，环比增速16.4%。海外建设/降本增效，齐头并进。销售不及预期、研发进展不及预期、政策影响、海外销售风险。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024082315120695b70dcb&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024082315120695b70dcb&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["688029","BK0251"],"gpt_icon":0},{"id":"2461842455","title":"南微医学(688029)：国际市场销售快速增长 业务毛利率显著提升","url":"https://stock-news.laohu8.com/highlight/detail?id=2461842455","media":"国金证券股份有...","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2461842455?lang=zh_cn&edition=full","pubTime":"2024-08-23 11:26","pubTimestamp":1724383594,"startTime":"0","endTime":"0","summary":"经营分析国际市场销售快速增长，海外区域成为核心增长支撑。从地区情况来看，2024 上半年公司国内市场收入7.06 亿元，同比+1.7%；国际市场收入6.24 亿元，同比+39.7%，海外成为公司核心增长支撑。可视化产品推广顺利，综合毛利率显著提升。一次性内科胆道镜在欧、美、日等国际市场推广顺利，逐步进入医院市场。同时可视化产品降本工作取得成效，公司综合毛利率达到67.94%，同比+4.2pct。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024082311263795b664ea&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024082311263795b664ea&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["688029","BK0251"],"gpt_icon":0},{"id":"2461397746","title":"南微医学(688029.SH)发布半年度业绩，净利润3.1亿元，同比增长17.47%","url":"https://stock-news.laohu8.com/highlight/detail?id=2461397746","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2461397746?lang=zh_cn&edition=full","pubTime":"2024-08-22 19:06","pubTimestamp":1724324768,"startTime":"0","endTime":"0","summary":"智通财经APP讯，南微医学(688029.SH)披露2024年半年度报告，报告期公司实现营收13.34亿元，同比增长16.28%;归母净利润3.1亿元，同比增长17.47%;扣非净利润3.06亿元，同比增长18.25%;基本每股收益1.66元。公司拟向全体股东每10股派发现金红利5元(含税)。报告期内，公司实现营业收入13.34亿元，较上年同期的11.47亿元增长16.28%，其中国内市场销售收入约7.06亿元，去年同期6.94亿元，同比增长1.73%;国际市场销售收入约6.24亿元，去年同期4.47亿元，同比增长39.72%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1168669.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["688029"],"gpt_icon":0},{"id":"2461391805","title":"南微医学：2024年半年度净利润约3.1亿元，同比增加17.47%","url":"https://stock-news.laohu8.com/highlight/detail?id=2461391805","media":"每日经济新闻","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2461391805?lang=zh_cn&edition=full","pubTime":"2024-08-22 18:10","pubTimestamp":1724321435,"startTime":"0","endTime":"0","summary":"每经AI快讯，南微医学 8月22日晚间发布半年度业绩报告称，2024年上半年营业收入约13.34亿元，同比增加16.28%；归属于上市公司股东的净利润约3.1亿元，同比增加17.47%；基本每股收益1.66元，同比增加17.73%。截至发稿，南微医学市值为108亿元。道达号“个股趋势”提醒：1. 南微医学近30日内北向资金持股量增加36.01万股，占流通股比例增加0.20%；2. 近30日内无机构对南微医学进行调研。每经头条——小米汽车亏损18亿元！","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202408221811369f479582&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":["earning"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202408221811369f479582&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["688029"],"gpt_icon":0},{"id":"2461539973","title":"南微医学最新公告：上半年净利润3.1亿元 同比增长17.47%","url":"https://stock-news.laohu8.com/highlight/detail?id=2461539973","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2461539973?lang=zh_cn&edition=full","pubTime":"2024-08-22 18:10","pubTimestamp":1724321411,"startTime":"0","endTime":"0","summary":"南微医学披露2024年半年报，公司上半年实现营业收入13.34亿元，同比增长16.28%；净利润3.1亿元，同比增长17.47%；基本每股收益1.66元。公司拟向全体股东每10股派发现金红利5元（含税）。以上内容由证券之星根据公开信息整理，由算法生成（网信算备310104345710301240019号），与本站立场无关，如数据存在问题请联系我们。本文为数据整理，不对您构成任何投资建议，投资有风险，请谨慎决策。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024082200033321.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688029"],"gpt_icon":0},{"id":"2461366390","title":"南微医学08月22日主力资金流入47万元 连续3日加仓","url":"https://stock-news.laohu8.com/highlight/detail?id=2461366390","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2461366390?lang=zh_cn&edition=full","pubTime":"2024-08-22 15:19","pubTimestamp":1724311156,"startTime":"0","endTime":"0","summary":"08月22日, 南微医学股价跌0.19%，报收57.59元，成交金额6437万元，换手率0.59%，振幅1.46%，量比0.84。南微医学今日主力资金净流入47万元，连续3日净流入，上一交易日主力净流入1139万元，今日环比减少95.87%。近一年数据显示，该股主力连续3日净流入后，次日上涨概率为40.00%，平均涨幅为1.98%。该股近5个交易日下跌4.02%，主力资金累计净流入3045万元；近20日主力资金累计净流入6399万元，其中净流入天数为12日。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024082215462595b32771&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024082215462595b32771&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["688029","BK0251"],"gpt_icon":0},{"id":"2460738015","title":"南微医学大跌5.04% 3家券商给予增持建议","url":"https://stock-news.laohu8.com/highlight/detail?id=2460738015","media":"智选洞察","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2460738015?lang=zh_cn&edition=full","pubTime":"2024-08-20 09:49","pubTimestamp":1724118571,"startTime":"0","endTime":"0","summary":"08月20日，南微医学股价大幅下跌，截至09点49分，南微医学下跌5.04%，报55.63元/股，创历史新低，成交5667万元，换手率0.53%，振幅4.97%。北向资金方面，南微医学08月16日获得北向资金增持2.27万股，截至08月16日，北向资金当前共持有南微医学336.44万股，市值1.87亿元，持股占流通股比为1.79%。最新财报显示，今年一季报，南微医学实现营业收入6.20亿元，同比增长12.72%，净利润为1.43亿元，同比增长41.36%，基本每股收益为0.76元。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240820094952a1d51825&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240820094952a1d51825&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK0251","688029"],"gpt_icon":0},{"id":"2458998526","title":"南微医学(688029.SH)股东Huakang减持期满 合计减持371.51万股","url":"https://stock-news.laohu8.com/highlight/detail?id=2458998526","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2458998526?lang=zh_cn&edition=full","pubTime":"2024-08-12 21:37","pubTimestamp":1723469861,"startTime":"0","endTime":"0","summary":"智通财经APP讯，南微医学(688029.SH)公告，公司股东Huakang Limited(简称“Huakang”)减持计划期限届满，Huakang以集中竞价交易、大宗交易方式合计减持371.51万股。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1163204.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["688029","BK0251"],"gpt_icon":0},{"id":"2458510461","title":"南微医学获得发明专利授权：“一种三臂夹”","url":"https://stock-news.laohu8.com/highlight/detail?id=2458510461","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2458510461?lang=zh_cn&edition=full","pubTime":"2024-08-10 02:34","pubTimestamp":1723228494,"startTime":"0","endTime":"0","summary":"证券之星消息，根据天眼查APP数据显示南微医学新获得一项发明专利授权，专利名为“一种三臂夹”，专利申请号为CN202010390270.3，授权日为2024年8月9日。本发明实施例的三臂夹能够在内镜微创手术中简单快捷且有效的对大的消化道缺损及操作困难部位的缺损进行夹持和缝合。今年以来南微医学新获得专利授权27个，较去年同期增加了80%。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024081000003219.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688029","BK0251"],"gpt_icon":0},{"id":"2457804145","title":"A股成价值洼地，科创利好催化不断","url":"https://stock-news.laohu8.com/highlight/detail?id=2457804145","media":"鹏华基金","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2457804145?lang=zh_cn&edition=full","pubTime":"2024-08-08 06:55","pubTimestamp":1723071313,"startTime":"0","endTime":"0","summary":"A股几大指数周三早盘基本上也是以红盘运行。外围市场剧烈动荡是A股市场最好的试金石，在近两周亚太市场普遍重挫的背景下，港股与A股都表现的较为坚韧。消息面上，近期科创相关催化不断。科创板的上市公司在A股市场中具有更强的研发能力以及成长性而备受市场关注，而在当下随着市场行情的不断调整，其投资性价比也与日俱增。周三市场反弹，科创100指数上涨超5%，可见其弹性之高。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240808065300aefdc14e&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240808065300aefdc14e&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["688032","688686","688001","688408","688278","688567","688383","688172","688639","688432","688318","688037","688361","688192","399300","688139","688166","688608","688439","688568","688208","688002","688281","688772","688798","688161","688520","688200","688066","688336","688498","688425","688526","688029","688083","688387","688484","688700","688006","588220","688347","688110","689009","688779","688575","688266","688333","688578","688100","688409","688016","688289","688326","688248","688106","688017","688050","688005","688327","688617","688343","688213","688107","688088","688366","688235","688582","688198","688789","688739","688516","688331","688276","688556","688055","688778","159982","688177","688007","688052","688322","688019","688536","688690","688097"],"gpt_icon":0},{"id":"2457835395","title":"【9家上市公司股票获重要股东增持，广安爱众增持金额最高】金十数据8月7日讯，数据显示，按变动截止日期为基准，8月6日，3家上市公司股票遭重要股东减持，南微医学遭重要股东减持73.","url":"https://stock-news.laohu8.com/highlight/detail?id=2457835395","media":"美港电讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2457835395?lang=zh_cn&edition=full","pubTime":"2024-08-07 09:09","pubTimestamp":1722992950,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.ushknews.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_meigang","symbols":["688029","600979","BK0251","BK0271","BK0056"],"gpt_icon":0},{"id":"2457461880","title":"8月6日南微医学发布公告，其股东减持73.85万股","url":"https://stock-news.laohu8.com/highlight/detail?id=2457461880","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2457461880?lang=zh_cn&edition=full","pubTime":"2024-08-06 20:01","pubTimestamp":1722945671,"startTime":"0","endTime":"0","summary":"证券之星消息，8月6日南微医学发布公告《南微医学:南微医学科技股份有限公司简式权益变动报告书》，其股东Huakang Limited于2024年7月25日至2024年8月6日间合计减持73.85万股，占公司目前总股本的0.3932%，变动期间该股股价上涨1.22%，截止8月6日收盘报61.5元。股东增减持详情见下表：根据南微医学2024年一季报公布的十大股东详情如下：以上内容由证券之星根据公开信息整理，由算法生成（网信算备310104345710301240019号），与本站立场无关，如数据存在问题请联系我们。本文为数据整理，不对您构成任何投资建议，投资有风险，请谨慎决策。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024080600039493.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0251","688029"],"gpt_icon":0}],"profile":{"ret":0,"listingDate":"2019-07-22","address":"江苏省南京市浦口区高新开发区高科三路10号","stockEarnings":[{"period":"1week","weight":0.0586},{"period":"1month","weight":-0.0171},{"period":"3month","weight":-0.0704},{"period":"6month","weight":-0.1711},{"period":"1year","weight":-0.1531},{"period":"ytd","weight":-0.3709}],"companyName":"南微医学科技股份有限公司","boardCode":"AI0035","perCapita":"18709股","boardName":"专用设备制造业","registeredCapital":"18784万元","compareEarnings":[{"period":"1week","weight":-0.0063},{"period":"1month","weight":-0.0146},{"period":"3month","weight":-0.0843},{"period":"6month","weight":-0.0552},{"period":"1year","weight":-0.0807},{"period":"ytd","weight":-0.0424}],"survey":" 南微医学科技股份有限公司的主营业务为微创医疗器械的研发、制造和销售。公司主要产品包括内镜诊疗器械、微波消融设备及耗材、一次性内镜。公司内镜诊疗器械主要包括活检类、止血和闭合类、EMR/ESD 类、扩张类、ERCP 类、EUS/EBUS类等六大类60多种上百个规格系列产品，微波消融主要包括微波消融仪和微波消融针系列产品。公司是我国内镜诊疗器械的主要制造商之一，是国内内镜诊疗器械、耗材细分领域中起步较早、创新能力强、产品线丰富、规模优势明显、迈向国际化的行业龙头企业。","serverTime":1724784838927,"listedPrice":52.45,"stockholders":"10040人(较上一季度减少3.02%)","compareStock":{"symbol":"000001.SH","name":"上证指数"}},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.26.2","shortVersion":"4.26.2","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"南微医学(688029)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供南微医学(688029)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"南微医学,688029,南微医学股票,南微医学股票老虎,南微医学股票老虎国际,南微医学行情,南微医学股票行情,南微医学股价,南微医学股市,南微医学股票价格,南微医学股票交易,南微医学股票购买,南微医学股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"南微医学(688029)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供南微医学(688029)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}